MLB Weekly Digest September 3rd Edition - NGSC Sports
Eczema And Asthma Share A Link. Can It Lead To New Treatments?
On the surface, asthma and eczema may not seem related — but two UC San Francisco researchers are collaborating in ways that could uncover new treatments based on underlying connections.
The collaboration is between two biomedical researchers, Mark Ansel, PhD, and Marlys Fassett, MD, PhD, who seem to come from different worlds.
Remove this text and use the embed button to add an image.
Collaborations across the lab and clinicAnsel is a UCSF professor of microbiology and immunology who studies how different molecules guide the development and behavior of immune cells, with a focus on why lungs become inflamed during asthma attacks.
Fassett is a dermatologist at UCSF Health who treats patients' itchy allergic reactions, like eczema, in the clinic. She's also a UCSF professor who studies the biology of eczema and related skin conditions.
But their chance connection two decades ago has blossomed into a collaboration that bridges the laboratory and clinic to advance the science of itch, allergy and asthma. Such collaborations are central to UCSF's pursuit of better therapies for patients — and they're already producing results.
"Our clinicians always want to do better for their patients, but they're also really interested in how disease works and they know that's the key to finding new ways to treat their patients," Ansel said. "That's part of the magic of this place."
Why is eczema so itchy?In 2012, Fassett arrived at UCSF to pursue her dermatology residency, armed with a joint MD-PhD degree from Harvard University and the Massachusetts Institute of Technology. One of the worst symptoms of eczema her patients experience is incessant itch, spurring them to scratch their sore skin and make things worse.
Fassett was curious about an immune protein known as the "itch cytokine" that had been previously discovered by other scientists. It was no surprise that it was abundant in the skin of her patients with eczema, but it wasn't clear what the protein was doing or how to get it under control.
There has to be interchange between clinicians and basic scientists to move the needle."
Mark Ansel, PhD
Ansel, who had mentored Fassett for three months in the early 2000s at Harvard, hadn't worked on the itch cytokine himself, but was familiar with similar immune proteins from his work on asthma. The itch cytokine and those asthma-related molecules were made by the same type of immune cell, the T-cell.
"These T-cells were in his scientific wheelhouse," Fassett says. "I already knew I could be very honest with Mark about both my excitement for the science and when things weren't working, which is actually a good thing in research."
Ansel invited Fassett to join his Parnassus research building lab, and Fassett began to split her time between itch experiments and attending to her patients.
Synergy from bench to bedsideIt wasn't long before Fassett and Ansel's research began to point to common mechanisms in many allergic and immunologic disorders, eczema and asthma among them.
"With asthma, there's an underlying, allergy-like immunity, driven by T-cells," says Ansel, chair of the UCSF Bakar ImmunoX Initiative, the campus hub for immunology. "One new drug, dupilumab, which targets several immune molecules in the lungs, has transformed care for many allergic-asthma patients and even some with COPD. Those same molecules are also in skin, and Marlys and her dermatology colleagues prescribe them to help people with eczema."
The itch cytokine remains the focus of both scientists, even as Fassett has left Ansel's laboratory to start her own research group. Together and independently, they're looking into other drugs that target the immune system, including nemolizumab — now in clinical trials for eczema — that might also treat asthma and other diseases.
"Immunology has had a big impact on cancer and many other diseases, even psychiatric diseases, in the last decade or two, but we still have a lot of work to do," Ansel says. "The real impactful insights keep coming from the community working together. There has to be interchange between clinicians and basic scientists to move the needle."
Dupixent Receives Green Light To Treat Asthma From Chinese National Medical Products Administration
Sanofi's innovative medicine Dupixent exhibited at the 6th China International Import Expo held in Shanghai in November 2023. [Photo provided to chinadaily.Com.Cn] French pharmaceutical company Sanofi announced on Nov 17 that its innovative biological agent Dupixent has been approved by the Chinese National Medical Products Administration for the treatment of asthma in individuals aged 12 and older.
Asthma is the top respiratory disease in China in terms of the number of patients, and has huge unmet medical needs.
A national study in 2019 showed that the morbidity of asthma among individuals aged 20 and above was 4.2 percent, and the numbers have been rising every year. Between 55 and 70 percent of the patients were in poorly controlled disease situations.
Dupixent brings a targeted etiologic treatment option to patients suffering from poorly controlled asthma, said Wayne Shi, president of Sanofi Greater China.
"This is also the company's 10th new product or indication approved in China this year. This shows the unprecedented speed we have achieved in bringing innovative products to the market to meet the health needs of the Chinese people and making contributions to the Healthy China 2030 Initiative," he added.
This is the sixth indication for the innovative injection Dupixent that has been approved in China over the past four years and the first in the respiratory field.
Emerging Dupilumab (Dupixent) Drug Insights And...
DUBLIN , Nov. 20, 2023 /PRNewswire/ -- The "Dupilumab Emerging Drug Insight and Market Forecast - 2032" report has been added to ResearchAndMarkets.Com's offering.
This report offers comprehensive insights into the use of dupilumab for bullous pemphigoid across the seven major markets.
It presents a detailed overview of dupilumab's application for bullous pemphigoid in the 7MM, encompassing the United States, EU4 (consisting of Germany, France, Italy, and Spain), the United Kingdom, and Japan, during the period from 2019 to 2032. The report includes an extensive description of the use of dupilumab for bullous pemphigoid.
Dupilumab, marketed as Dupixent, is a monoclonal antibody designed to target the a-chain of the interleukin (IL)-4 receptor. Its primary function is to inhibit the biological effects of cytokines IL-4 and IL-13, both of which play pivotal roles in the TH2 response (Sastre, 2018).
Dupilumab has received approval in the United States for several indications, including the treatment of moderate-to-severe atopic dermatitis (AD) in patients aged 12 years and older who do not respond well to topical prescription therapies or are unable to use them. It is also approved for use in conjunction with other asthma medications to maintain the treatment of moderate-to-severe eosinophilic asthma or asthma dependent on oral steroids in patients aged 12 years and older whose asthma remains uncontrolled with current treatments.
Additionally, it is approved for use in combination with other medications for the maintenance treatment of chronic rhinosinusitis with nasal polyposis (CRSwNP) in adults with uncontrolled symptoms. For adolescents aged 12 and older, it is recommended that dupilumab be administered under the supervision of an adult.
In addition to its existing approvals, Regeneron and Sanofi are actively researching the potential applications of dupilumab in various clinical development programs targeting diseases driven by allergic and Type 2 inflammation. These include conditions like peanut allergy, grass allergy, pediatric AD, pediatric asthma, eosinophilic esophagitis, chronic obstructive pulmonary disease (COPD), bullous pemphigoid (BP), prurigo nodularis, chronic spontaneous urticaria, and allergic bronchopulmonary aspergillosis.
The report provides insights into the mechanism of action, recommended dosage and administration, research and development progress, and regulatory milestones, as well as other ongoing developmental activities. Furthermore, it offers future market assessments, including a forecast analysis of the dupilumab market for bullous pemphigoid in the 7MM, SWOT analysis, perspectives from analysts, a comprehensive overview of market competitors, and a brief overview of emerging therapies for bullous pemphigoid.
Dupilumab Analytical Perspective
In-depth Dupilumab Market Assessment
This report provides a detailed market assessment of dupilumab for bullous pemphigoid in the seven major markets, i.E., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2023 to 2032.
Dupilumab Clinical Assessment
The report provides the clinical trials information of dupilumab for bullous pemphigoid covering trial interventions, trial conditions, trial status, start and completion dates.
Report Highlights
Scope of the Report
Key Topics Covered:
1. Report Introduction
2. Dupilumab Overview in bullous pemphigoid
2.1. Product Detail
2.2. Clinical Development
2.2.1. Clinical studies
2.2.2. Clinical trials information
2.2.3. Safety and efficacy
2.3. Other Developmental Activities
2.4. Product Profile
3. Competitive Landscape (Marketed Therapies)
4. Competitive Landscape (Late-stage Emerging Therapies)
5. Dupilumab Market Assessment
5.1. Market Outlook of Dupilumab in bullous pemphigoid
5.2. 7MM Analysis
5.2.1. Market Size of Dupilumab in the 7MM for bullous pemphigoid
5.3. Country-wise Market Analysis
5.3.1. Market Size of Dupilumab in the United States for bullous pemphigoid
5.3.2. Market Size of Dupilumab in Germany for bullous pemphigoid
5.3.3. Market Size of Dupilumab in France for bullous pemphigoid
5.3.4. Market Size of Dupilumab in Italy for bullous pemphigoid
5.3.5. Market Size of Dupilumab in Spain for bullous pemphigoid
5.3.6. Market Size of Dupilumab in the United Kingdom for bullous pemphigoid
5.3.7. Market Size of Dupilumab in Japan for bullous pemphigoid
6. SWOT Analysis
7. Analysts' Views
For more information about this report visit https://www.Researchandmarkets.Com/r/52yewu
About ResearchAndMarkets.Com
ResearchAndMarkets.Com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Media Contact:
Research and MarketsLaura Wood, Senior Managerpress@researchandmarkets.Com
For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1904 Fax (outside U.S.): +353-1-481-1716
Logo: https://mma.Prnewswire.Com/media/539438/Research_and_Markets_Logo.Jpg
SOURCE Research and Markets
© 2023 Benzinga.Com. Benzinga does not provide investment advice. All rights reserved.
Comments
Post a Comment